Concepedia

Publication | Closed Access

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

DOI

202

Citations

15

References

2010

Year

Stephan Petersenn, Jochen Schopohl, Ariel Barkan, Pharis Mohideen, Annamaria Colao, Roger Abs, A. Buchelt, Yu‐Yun Ho, Ke Hu, Andrew J. Farrall,
The Journal of Clinical Endocrinology & Metabolism

Abstract

Pasireotide is a promising treatment for acromegaly. Larger studies of longer duration evaluating the efficacy and safety of pasireotide in patients with acromegaly are ongoing.

References

YearCitations

Page 1